For recurrent or persistent macular edema due to central retinal vein occlusion of the following anti
Conditions
Interventions
Intravitreal administration of Aflibercept(Genetical Recombination)(EYLEA)
Sponsors
Nagasaki University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with macular edema due to central retinal vein occlusion. 2.Central retinal thickness-=>250µm 3.Point visual acuity less than 0.9 4.Patients who had received treatment with bevacizumab or ranibizumab for macular edema due to central retinal vein occlusion. 5.Age of patients 20years of age or older at the time of acquisition agreement. 6.After receiving a sufficient explanation upon participation in this study,on a full understanding,patients who obtained the document voluntary consent of the patient himself
Exclusion criteria
Exclusion criteria: 1.Patients who underwent the pan-retinal photocoagulation within 3 months. 2.Patients who underwent photocoagulation treatment for macular edema within 3 months. 3.Patients treated with steroids to intraocular within 3 months. 4.The patients with a history of hypersensitivity to the study drug. 5.Patients who developed heart and cerebrovascular disease severe within 6 months. 6.Patients attending physician was deemed inappropriate as a subject.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.The improvement rate of best corrected visual acuity at six months after the Aflibercept injection. 2.Presence or absence of exudative change, the changes of central retinal thickness and foveal choroidal thickness by OCT at 6 and 12 months after the Aflibercept injection. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.The retinal blood flow changes measureed by LSFG at 6 and 12 months after the Aflibercept injection. 2.Duration from Aflibercept injection to recurrence. 3.Adverse event | — |
Countries
Japan
Contacts
Public ContactMakiko Matsumoto
Nagasaki University Hospital Ophthalmology
Outcome results
None listed